secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2026-07-16T11:36:19+00:00
Accession:  0001628280-26-048377
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abbott Q2 adjusted EPS $1.31; raises FY2026 EPS guidance to $5.45-$5.60
-----------------------------------------------------------------------

- Q2 reported sales $12.6B (+13.0% reported, +4.8% comparable); GAAP EPS $0.53, adjusted EPS $1.31.
- Full-year 2026 adjusted EPS guidance raised to $5.45-$5.60 from $5.38-$5.58; comparable sales growth reaffirmed at 6.5%-7.5%.
- Medical Devices comparable sales +8.4%; Diabetes Care CGM comparable sales +9.5%.
- Returned $2.1B to shareholders in Q2 via dividends and share repurchases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000162828026048377/0001628280-26-048377-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000162828026048377/abt-20260716.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-048377

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer